Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase

Gesmundo, Iacopo; Blasio, Laura di; Banfi, Dana; Villanova, Tania; Fanciulli, Alessandro; Favaro, Enrica; Gamba, Giacomo; Musuraca, Chiara; Rapa, Ida; Volante, Marco; Munegato, Stefania; Papotti, Mauro; Primo, Luca; Ghigo, Ezio; Granata, Riccarda

doi:10.1016/j.canlet.2019.02.028

Cited by 22 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current positive associations with PPI use include enterochromaffin-like (ECL) hyperplasia, along with gastric, pancreatic, and prostate cancer. [106][107][108][109][110][111] Negative associations with PPI use include breast, colorectal, and hepatocellular carcinoma. [112][113][114] Gastric cancer is a significant burden globally.…”

Section: Do Ppis Really Cause Cancer?mentioning

confidence: 99%

Potential proton pump inhibitor–related adverse effects

Perry

Sonu

Scarpignato

et al. 2020

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are one of the most common medications taken by patients worldwide. PPIs are used to treat acid‐related disorders, including gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori infection, and nonsteroidal anti‐inflammatory drug/stress ulceration. For some of these diseases, long‐term treatment is necessary. With such prolonged use, concern and investigation into potential adverse effects has increased. In addition, data are available regarding potential anticancer effects of PPIs, especially regarding solid tumors. The aim of this review is to assess the literature on PPIs with regard to common concerns, such as drug–drug interactions, the intestinal microbiome, dementia and central nervous system disease, and osteoporosis, as well as to highlight potential negative and positive impacts of the drug in cancer.

show abstract

Section: Do Ppis Really Cause Cancer?mentioning

confidence: 99%

Potential proton pump inhibitor–related adverse effects

Perry

Sonu

Scarpignato

et al. 2020

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…Interestingly, we found that calcitriol increases the proportion of cells in the quiescent phase of cell cycle (G 0 /G 1 ), while reducing those in G2/M, indicating that the antiproliferative effects are associated with cell cycle arrest, in line with results in other cancer cells ( 8 , 38 ). Furthermore, calcitriol inhibited the expression of c-Myc and cyclin A, D1 and D2 , all involved in the control of cell cycle ( 22 , 24 , 30 , 49 ), in keeping with its ability to suppress the expression of c-Myc-regulated genes and to promote cell cycle arrest and inhibition of cyclins in both normal and cancer cells ( 30 , 50 , 51 ). c-Myc is a protooncogene frequently deregulated in many human cancers, whose inhibition induces apoptosis and sensitizes MPM cells to drug-induced cytotoxicity ( 52 ); moreover, we recently showed that c-Myc is implicated in the antitumor effects of growth-hormone releasing hormone (GHRH) antagonists in MPM cell lines ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

“…Cell cycle analysis was performed as described previously ( 24 ), using the Muse Cell Cycle Kit (Merck-Millipore, Burlington, MA, USA) according to the manufacturer's instructions. Briefly, 5 × 10 4 cells were seeded in 60-mm dishes and after 48 h incubated with different concentrations of calcitriol in medium supplemented with 2.5% FBS for 24 h. Cells were then detached with phosphate buffered saline (PBS) 1X/ethylenediaminetetraacetic acid (EDTA) (5 mM), centrifuged (1,500 rpm, 5 min) and fixed with pre-cooled ethanol.…”

Section: Methodsmentioning

confidence: 99%

Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells

et al. 2020

Self Cite

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, often associated with exposure to asbestos and characterized by poor prognosis and limited treatment options. The biologically active form of vitamin D, calcitriol, exerts anticancer effects in many cell types, both alone and in combination with chemotherapy drugs, through binding to vitamin D receptor (VDR); however, the role of calcitriol in MPM is still unknown. This study aimed to determine the potential antitumor role of calcitriol in MPM. The results showed that calcitriol reduces cell viability and proliferation in human MPM cells lines, which express both cytoplasmic and nuclear VDR; furthermore, calcitriol potentiated the inhibitory activity of the chemotherapy drug PEM. These effects were paralleled by cell cycle arrest and inhibition in expression of c-Myc and cyclins involved in cell cycle progression. Exposure of MPM cells to calcitriol also produced an alteration in mitochondrial function and inhibition in the expression of respiratory chain complex subunits. Finally, the inhibitory effects of calcitriol were also observed on viability of human primary MPM cells. Collectively, these results indicate a novel anticancer role for calcitriol in MPM, suggesting potential for vitamin D derivatives, alone or in combination with chemotherapy, in the treatment of this malignancy.

show abstract

“…Ключові слова: рак; передміхурова залоза; пухлинні маркери. ВСТУП У структурі онкологічної патології у чоловіків рак передміхурової залози (РПЗ) посідає провідні позиції [1,2], при цьому є другою за частотою причиною смерті від злоякісних новоутворень [3,4]. Захворюваність та смертність внаслідок РПЗ в усьому світі щорічно підвищуються [5,6].…”

unclassified

“…Значимость отдельных маркеров при различных вариантах течения рака предстательной железы О.Ю. Столярова 1 , Ю.В. Думанский 2 , М.И.…”

unclassified

Значимість Окремих Маркерів При Різних Варіантах Перебігу Раку Передміхурової Залози

2020

clinicaloncology

View full text Add to dashboard Cite

Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase

Cited by 22 publications

References 46 publications

Potential proton pump inhibitor–related adverse effects

Potential proton pump inhibitor–related adverse effects

Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells

Значимість Окремих Маркерів При Різних Варіантах Перебігу Раку Передміхурової Залози

Contact Info

Product

Resources

About